Close Menu

NEW YORK – The US Food and Drug Administration expanded the approval of niraparib (GlaxoSmithKline's Zejula) as a fourth- or later-line treatment option for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.